Taclonex Ointment is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older.
According to Symphony Health Solutions, brand sales were about $110m over the last 52-weeks.
Perrigo chairman, president and CEO Joseph Papa said Taclonex ointment was the result of the continued hard work and dedication of our Perrigo Rx team.
"This launch is another example of Perrigo’s investment and commitment to making quality healthcare more affordable for consumers," Papa said.
The company is focused in the development, manufacturing and distributing of over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri.